MedTrace Logo

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

NCT06783881 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-16

No results posted yet for this study

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Kylo-12

Administered SC.

DRUG

Placebo

Administered SC.

Sponsors & Collaborators

  • Kylonova (Xiamen) Biopharma co., LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-12
Primary Completion
2025-12-19
Completion
2026-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783881 on ClinicalTrials.gov